PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community remains optimistic for a cure or disease modifying treatment for Alzheimer’s, with particular faith in the amyloid hypothesis. Industry, advocacy groups, academia, and many other stakeholders in clinical development continue to embrace new technologies and data science with the hope that one day these will contribute toward bringing treatments to the right patients at the right stage of the disease.
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.
Achieving Challenging Recruitment Goals and Timelines in a Pediatric Type 2 Diabetes Study
Recruiting pediatric patients for type 2 diabetes mellitus (T2DM) studies is extremely challenging. Patients are difficult to identify and often face…
Introduction to Patient Feasibility
Patient Feasibility is an area under-explored in the clinical trial industry. Currently, protocol and site feasibility are the primary methods of…